Mohammad B. Haskali

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

James P Buteau, Andrew Martin, Louise Emmett et al. · The Lancet Oncology · 2022 · 239 citations

Biomarker (Medicine), Prognostic Biomarkers, Urology +7

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet Oncology · 2023 · 172 citations

Urology, Overall Survival, Genitourinary Cancer +8

Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study

Renu Eapen, James P Buteau, Price Jackson et al. · European Urology · 2023 · 74 citations

Phase 1/2, Urology, Surgical Oncology +7

A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper‐64 with High Tumor Uptake and Retention

Nicholas Zia, Carleen Cullinane, Jessica Van Zuylekom et al. · Angewandte Chemie International Edition · 2019 · 52 citations

First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [⁶⁸Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma

Michael S. Hofman, Ben Tran, Darren R. Feldman et al. · Journal of Nuclear Medicine · 2024 · 49 citations · Full text